CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Verogen›
Library
Verogen

Verogen

Operating Status: Acquired Subsidiary

Forensic next-generation sequencing company offering the ForenSeq workflow, MiSeq FGx system, and human identification software; a QIAGEN subsidiary.

Operating headquarters
San Diego, CA, US🇺🇸
Loading
Overview
Compare
Employees
Library

Verogen - Library

verogen.com·Crawled Oct 9, 2026·

Topics

Publication type

Content origin
Row density

Product

6 pages
  1. Capabilities/capabilities

    Short tandem repeat markers (STRs) are a constant in most human identification applications, but STRs still have more potential. Get better insights with our innovative technology. Whether you’re failing to recover enough information from a degraded sample, have insufficient sample to run the tests needed to get a conclusive answer, struggle to resolve minor contributors in a mixture, or want to avoid the complications of capillary electrophoresis (CE), Verogen NGS solutions are here to help.

  2. Law Enforcement Resources/law-enforcement-forensic-investigative-genetic-genealogy

    Forensic investigative genetic genealogy (FIGG) is a powerful tool for solving violent crimes such as homicides or sexual assaults, and identifying human remains from missing persons investigations and conflict zones.

  3. Product Documentation/resources/product-documentation
  4. Products/products

    Discover the Verogen line of products centered around the MiSeq FGx® Forensic Genomics System.

Blog

6 pages
  1. A Look Back at the Scientific Literature of 2018/verogen-annual-literature-review-2018

    When I look back on 2018, I see a year dominated in the journals by massively parallel sequencing (MPS) in many facets.  While it would be exhausting to

  2. Highlights from the 38th Spurenworkshop in Basel, Switzerland/spurenworkshop-highlights

    In 2014, Illumina hosted its first workshop dedicated entirely to the potential offered by Massively Parallel Sequencing for forensic applications, in

  3. NGS Interpretation Guidelines Published by SWGDAM/ngs-swgdam-interpretation-guidelines

    The Scientific Working Group on DNA Analysis Methods (SWGDAM) has released interpretation guidelines for forensic DNA testing laboratories performing next

  4. Publications/resources/publications

    Learn more about popular topics and find resources that will help you with all of your Verogen products.

Press

6 pages
  1. A message to Verogen customers about the GEDmatch partnership/a-message-to-verogen-customers-about-the-gedmatch-partnership

    We are pleased to share news that has far-reaching benefits for our company, our customers, and our scientific and law enforcement partners. Verogen

  2. Cellmark and Verogen Collaborate to Make the Next Generation of Forensic DNA Analysis Available to UK Police/cellmark-and-verogen-bring-next-gen-forensic-dna-to-uk

    Cellmark Forensic Services and Verogen have teamed up to make next-gen forensic DNA testing available in the UK.

  3. CFSRE and Verogen Team Up to Accelerate the Implementation of Next Generation Sequencing for Law Enforcement and Practitioner Communities/cfsre-and-verogen-collaborate-to-accelerate-implementation-of-forensic-ngs

    CFSRE and Verogen have teamed up to accelerate implementation of Next Generation Sequencing for law enforcement and practitioner communities.

  4. FBI Approves Verogen’s Next-Gen Forensic DNA Technology for National DNA Index System (NDIS)/ndis-approval-of-miseq-fgx

    For Immediate Release San Diego, CA, May 2, 2019—Verogen, Inc., the world’s first DNA sequencing company dedicated to forensic science, announced today

Comparison

1 page
  1. ForenSeq™ Outperforms GlobalFiler™ in Sensitivity Comparison Study/sensitivity-comparison

    In a poster presented at the American Academy of Forensic Sciences 2018 Annual Scientific Meeting in Seattle, WA, a team at Western Carolina University

About

4 pages
  1. Company/company

    Verogen serves those who pursue the truth. Introducing the world’s first sequencing company solely dedicated to forensic science.

  2. Corporate Social Responsibility/company/corporate-social-responsibility

    Verogen is committed to thinking future-forward, both in the lab and for the environment.

  3. Events/company/events

    Learn about the events and tradeshows that Verogen will be participating in this year.

  4. Grants and Funding/resources/grants-and-funding

Contact

1 page
  1. Contact Us/contact-us

    We create thoughtfully tailored genomic solutions for forensic DNA labs. Let us help you overcome limitations and solve more cases.

Homepage

1 page
  1. Homepage/

    Take your forensic investigations further with our comprehensive portfolio of next-generation sequencing (NGS) solutions.

Privacy

2 pages
  1. Cookie Policy/cookie-policy

    Cookie Policy We use cookies on our site. Cookies store some information on your computer. This page tells you about the kind of cookies we use. What is a

  2. Privacy Policy/privacy-policy

    Privacy Policy This Policy governs the use of personal data which you provide to us via our website. Personal data is any or all data relating to a

Terms & Conditions

2 pages
  1. Terms and Conditions of Sale/termsandconditions

    Definitions “Agreement” means these terms and conditions of sale, the Support Plan and the Quotation. “Consumable(s)” means Seller branded reagents and

  2. Verogen Terms and Conditions for Products and Services/tandc

    Click Here for Verogen's Terms and Conditions for Products and Services